Tradestie Institutional Equity Comparison Engine

BMRA vs NPCE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NPCE Overall Edge

NPCE Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Neuropace, Inc. Common Stock (NPCE) driven by superior Valuation, Growth & Margin, Momentum & Technical while BMRA counters with relative strength in Options & Structure. Fundamentally, BMRA trades at N/M Forward P/E with -125.2% operating margin (-8.3% YoY revenue) versus NPCE at 138.9x Forward P/E and -11.3% operating margin (-15.5% YoY). In options structure, BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NPCE sits in BREAKDOWN (45th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NPCE
BMRA N/M vs NPCE 138.9x Fwd P/E
Growth & Margin Winner NPCE
Op Margin -125.2% vs -11.3% ยท YoY -8.3% vs -15.5%
Momentum & Technical Winner NPCE
1Y -45.6% vs -39.5% ยท 52W Pos 5% vs 16%
Options & Structure Winner BMRA
UNCLASSIFIED (N/A IV) vs BREAKDOWN (45th %ile IV)
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
1M Return -26.49%
1Y Return -45.6%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
NPCE NASDAQ
Neuropace, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$7.75
+2.45% 1D
Market Cap $412.6M
1M Return -36.72%
1Y Return -39.54%
Forward P/E 138.9x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 44.0 Flow 68.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMRA -45.6% NPCE -39.54% Spread: +6.06 pp (NPCE Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BMRA Revenue NPCE Revenue BMRA Op. Margin NPCE Op. Margin Margin Edge
FY2019 $10M N/A -46.4% N/A BMRA
FY2020 $10M $40M -41.0% -31.7% NPCE
FY2021 $10M $50M -104.2% -52.5% NPCE
FY2022 $20M $50M -24.0% -89.6% BMRA
FY2023 $10M $70M -135.3% -41.5% NPCE
FY2024 $10M $80M -117.6% -27.1% NPCE
FY2025 $10M $100M -96.7% -16.3% NPCE
FY2026 $0M N/A -119.5% N/A BMRA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMRA (3) vs NPCE (7)
Institutional Metric BMRA NPCE Criterion Row Winner
Market Capitalization Scale $6.0M $412.6M Larger Scale NPCE
Trailing P/E Ratio Valuation N/M 138.9x Lower Multiple NPCE
Forward P/E Ratio Valuation N/M 138.9x Lower Multiple NPCE
Revenue Growth (YoY) Growth -8.3% -15.5% Higher Growth BMRA
Operating Margin (TTM) Profitability -125.2% -11.3% Higher Margin NPCE
Net Profit Margin Profitability -115.5% -18.4% Higher Margin NPCE
Return on Equity (ROE) Capital Efficiency -113.8% -106.5% Higher ROE NPCE
52-Week Range Position Momentum 5% ($1โ€“$3) 16% ($5โ€“$20) Stronger Trend NPCE
Beta / 30D Volatility Risk Regime 0.67ฮฒ ยท 62% Vol 1.35ฮฒ ยท 138% Vol Lower Realized Risk BMRA
Unified Institutional Score Composite Signal 44.5 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite BMRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMRA vs NPCE Buy Guide
BMRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BMRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NPCE BREAKDOWN
133d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 45th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NPCE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMRA nor NPCE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.